Private
The Department of Homeland Security (DHS) Countering Weapons of Mass Destruction Office (CWMD) has awarded a contract to Smiths Detection to provide 110 radiation portal monitors (RPM).
The RPMs would be deployed across land border crossings throughout the country. The passive checkpoints... Read More »
The United States federal government exercised two options on contracts with Merck and Ridgeback Biotherapeutics this week to purchase an additional 1.4 million courses of the investigational oral antiviral molnupiravir for use against COVID-19.
This deal will amount to approximately $1 billion... Read More »
With approval from the U.S. Food and Drug Administration (FDA) now in hand, INOVIO intends to proceed with a Phase 3 segment of its INNOVATE trial for the COVID-19 vaccine candidate INO-4800 in the United States.
Authorization followed a partial clinical hold on the candidate, while the FDA... Read More »
For at least eight months following a single dose, the REGEN-COV COVID-19 drug cocktail developed by Regeneron Pharmaceuticals, Inc. could provide affiliated risk reductions of 81.6 percent, according to a new analysis of a Phrase 3 trial.
That trial, jointly run by Regeneron and the National... Read More »
MSA Safety Inc. earned a $4 million contract from the U.S. Department of Health and Human Services (HHS) last week to produce elastomeric air-purifying respirators to be added to the Strategic National Stockpile (SNS).
The MSA’s Advantage 290 Air-Purifying Respirator (APR) consists of a... Read More »
Interim data from Pfizer Inc.’s novel COVID-19 antiviral candidate, PAXLOVID, revealed an oral treatment with the ability to cut the risk of hospitalization and death by as much as 89 percent among adult patients.
These results, pulled from the randomized Phase 2/3 EPIC-HR (Evaluation of... Read More »
On Wednesday, the U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) announced it had selected Northeastern University to lead a consortium of U.S. academic institutions for a new Center of Excellence for Engineering Secure Environments from Targeted Attacks... Read More »
The antiviral Molnupiravir became the first oral treatment for COVID-19 to receive authorization this week, winning approval from the U.K.’s Medicines and Healthcare Products Regulatory Agency for treatment of mild-to-moderate COVID-19 cases in adults.
Specifically, users must have had at... Read More »
The World Health Organization (WHO) made its eighth emergency use listing (EUL) for a COVID-19 vaccine this week, granting that honor to Bharat Biotech’s COVAXIN.
COVAXIN is formulated from an inactivated SARS-CoV-2 -- the virus that causes COVID-19 -- antigen. Use of the vaccine by adults was... Read More »
As world leaders gather in Glasgow for the UN Climate Change Conference, COP26, a new global partnership has formed to focus on the impact of climate change on terrorism, the group said Tuesday.
The National Consortium for the Study of Terrorism and Responses to Terrorism (START), Pool Re... Read More »
A Q2 Solutions Co., Ltd. lab facility in Beijing, China, became the first East Asian lab to join the Coalition for Epidemic Preparedness Innovations’ (CEPI) centralized COVID-19 lab network this week.
“I am delighted to today welcome Q2 Solutions’ facility in Beijing to this group of... Read More »
The failures, successes, and lessons learned from the rollout of COVID-19 vaccines should be incorporated immediately into future pandemic vaccine planning if the world hopes to avoid the delays and pitfalls of the modern ecosystem, according to a new report from the Johns Hopkins Center for Health... Read More »
Last week, the U.S. Food and Drug Administration (FDA) notified Moderna, Inc. that an assessment of an emergency use authorization request for its COVID-19 vaccine to be used on adolescents may not be completed before January 2022.
The delay was due to a stated necessity to evaluate recent... Read More »
A new partnership between the Biomedical Advanced Research and Development Authority (BARDA) and RIVANNA seeks to develop the company’s Accuro XV device for the release of a portable 3D fracture detection and diagnosis system without radiation.
The rapid-working system is based on ultrasound... Read More »
In collaboration with the Indianapolis Metropolitan Police Department (IMPD), the Defense Advanced Research Projects Agency’s (DARPA) SIGMA+ program announced Friday it had recently concluded a three-month-long pilot study of sensors intended to support early detection of weapons of mass... Read More »
The Access to COVID-19 Tools (ACT) Accelerator released a new strategic plan last week that seeks $23.4 billion from international investors by September 2022 to patch inequalities in access to COVID-19 tests, treatments, vaccines, and personal protective equipment.
This is particularly... Read More »
Boeing officials announced that the aerospace company has broken ground on a 370,000 square-foot maintenance, repair and overhaul (MRO) facility located at Cecil Airport in Jacksonville, Fla.
The endeavor would support the company's ability to deliver readiness outcomes for domestic government... Read More »
Reckoning with the threat of diseases present and future, the Biomedical Advanced Research and Development Authority (BARDA) announced a new collaboration last week with BD (Becton, Dickinson and Company) to develop and win approval for diagnostics capable of identifying COVID-19, influenza, as... Read More »
FirstNet, which officials have deemed public safety's network built to strict specifications and requirements, is touting over 2.8 million nationwide connections through 18,500 public safety agencies.
"In less than five years, we've built a network with and for America's first responders and... Read More »
This week, an agreement was reached between the Medicines Patent Pool (MPP) and Merck pledges low-cost access to the investigational oral COVID-19 antiviral molnupiravir worldwide, with a particular focus on 105 low and middle-income countries (LMICs).
Jointly developed by Merck and Ridgeback... Read More »
Biotechnology company INOVIO finished enrollment for a West Africa-based Phase 1B clinical trial of INO-4500, its DNA vaccine candidate for Lassa Fever, this week.
A full complement of 220 participants will participate in this first trial for a Lassa fever vaccine in West Africa. The area was... Read More »
Moderna Inc. announced Monday it had a new memorandum of understanding to make up to 110 million doses of the Moderna COVID-19 vaccine available to the African Union.
The company said it is prepared to deliver the first 15 million doses in the fourth quarter of 2021, with 35 million doses... Read More »
With the investment of $26 million announced this week, the Centers for Disease Control and Prevention (CDC) hopes to modernize the science of infectious disease prediction and analytics.
The first investments from CDC’s Center for Forecasting and Outbreak Analytics (CFA) -- which is expected... Read More »
According to top line data from a Phase 2/3 study of Moderna’s COVID-19 vaccine among children ages 6-11, released this week, the company determined that two doses given a month apart produced a strong antibody response -- stronger, even, than those seen in adults.
Conducted in collaboration... Read More »
In recent weeks, the U.S. Department of Health and Human Services (HHS) has invested more than $562 million into U.S. companies to boost domestic manufacturing of COVID-19 tests and supplies.
These funds, pulled from the American Rescue Plan Act, have benefited supplies such as pipette tips,... Read More »
Novartis officials said the company has established an agreement leveraging its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding Pfizer-BioNTech vaccine support.
The agreement targets the fill and finish of more than 50 million doses in 2021 at the Novartis... Read More »
Lawrence Livermore National Laboratory (LLNL) announced it had joined the international Human Vaccines Project (HVP) Thursday, bringing its expertise and computing resources to the project to aid the development of a universal coronavirus vaccine and to improve understanding of immune response.... Read More »
Recognizing the delays that have plagued low-income countries at nearly every aspect of the COVID-19 pandemic, the Bill & Melinda Gates Foundation announced this week a pledge of up to $120 million to accelerate access to the antiviral drug molnupiravir among low-income nations.
Molnupiravir is... Read More »
Results arrived this week for a Phase 3 trial of Valneva SE’s COVID-19 vaccine candidate, VLA2001, and they revealed neutralizing antibody activity greater than 95 percent, along with broad T-cell responses and significant tolerability.
It was reported that the inactivated, adjuvanted vaccine... Read More »
Lockheed Martin has secured a $9,672,781 Army Project Agreement to continue developing the Terrestrial Layer System (TLS) program for the branch's tactical vehicles.
The action via the Army's Consortium Management Group (CMG)/Consortium for Command, Control, and Communications in Cyberspace (C5)... Read More »
The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative split $77.7 million among 12 new contract awards last week for potential, rapid SARS-CoV-2 diagnostic tests.
Part of the RADx Tech program, which gathered a panel of technical, regulatory and business... Read More »
Food and Drug Administration (FDA) officials said the agency will conduct a Nov. 30 meeting via its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss a COVID-19 oral treatment.
The FDA indicated the effort would focus on Merck and Ridgeback’s request for an emergency use authorization... Read More »
Following two successful Phase 3 trials of more than 6,000 patients, the United States Food and Drug Administration (FDA) last week accepted the Regeneron Pharmaceuticals, Inc. anti-COVID-19 cocktail known as REGEN-COV for priority review.
REGEN-COV is a mix of the antibodies casirivimab and... Read More »
The all-star team of government officials, scientists and industry executives who tackled COVID-19 made great strides in the development of an effective vaccine against the novel virus, but that is no guarantee that the United States will be ready for the next pandemic that rears its head, speakers... Read More »
The first participant in a new trial phase recently received a dose of a vaccine candidate against chikungunya disease that is being developed by Emergent BioSolutions Inc.
“Emergent has achieved a major milestone as we begin our phase 3 study for our single-dose chikungunya vaccine... Read More »
